Monthly Archives: August 2021


Intensive BP Control Beneficial in Chinese Population

A Chinese multicenter, randomized, controlled trial concluded that intensive treatment with a systolic blood-pressure (SBP) target of 110 to less than 130 mm Hg resulted in a lower incidence of cardiovascular events than standard treatment with a target of 130 to less than 150 mm Hg. Of the 8511 hypertensive […]


Empagliflozin Effective in HFpEF

A double-blind, randomized trial revealed that empagliflozin reduced the combined risk of cardiovascular death or hospitalization for heart failure (HF) in patients with HF and a preserved ejection fraction (HFpEF), regardless of the presence or absence of diabetes. The trial included 5988 patients (average 72 years, about 45% women, and […]


Gut Microbiome Might Be the Link of Healthy Foods and Lower BP

A community-based cohort study in Germany suggested that the composition of the gut microbiome might explain the cross-sectional association of habitual flavonoid and flavonoid-rich food intake with blood pressure (BP). The study included 904 participants, and 16S ribosomal RNA was sequenced for the gut microbiome composition. Higher total flavonoid intakes […]